12 results about "Vitamin analog" patented technology

The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.

The invention relates to a purple jade extract as well as a preparation method and application thereof, and belongs to the field of plant extracts. According to the purple jade extract as well as the preparation method and the application thereof provided by the invention, the extraction of flavonoid substances rich in a dendrobium devonianum variety'purple jade 'is completed for the first time, the extract with the total flavonoid content of more than or equal to 17% is obtained, and the condition that the dendrobium devonianum variety'purple jade' contains two substances, namely rutin and vicenin-2, is determined through qualitative and quantitative analysis. Through verification, the purple jade extract disclosed by the invention has a good antioxidant function, and the total antioxidant capacity of the purple jade extract is close to that of a water-soluble vitamin E analogue Trolox (6-hydroxy-2, 5, 7, 8-tetramethylchromane-2-carboxylic acid) with the equivalent weight of 4mM. According to the purple jade extract as well as the preparation method and the application thereof, a scientific basis is provided for application of purple jade in related directions, and the purple jade extract can be used as an intermediate for development of purple jade series products (such as in the fields of medicine, food, daily necessity development and the like).

The present invention relates to a pharmaceutical foam composition comprising a corticosteroid and a Vitamin D analogue for topical administration to a patient in need thereof, such as for the treatment of plaque psoriasis. The present invention also relates to a process for preparing the composition and a suitable container system for administration of the composition. Preferably, the invention relates to the topical administration of betamethasone dipropionate and calcipotriene with one or more pharmaceutically acceptable excipients and propellants where the composition is stable in the container system coated with a coating material selected from the group comprising of epoxyphenol resin, modified polyesters, microflex coating or polyacrylates.

The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.

The present disclosure provides novel Vitamin D analogs, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly melanoma, ovarian, and breast cancers. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

The application discloses application of PAK4 inhibitor comp55 in preparation of a medicine for inhibiting formation of tumor-related fibroblasts, and belongs to the technical field of medicine application. The application first proposes the application of PAK4 inhibitor comp55 in preparation of the medicine for inhibiting formation of tumor-related fibroblasts, and provides a new scheme for the medicine for inhibiting formation of tumor-related fibroblasts. The application first proposes that PAK4 inhibitor comp55 inhibits formation of CAFs by targeting PAK4. The application first proposes that PAK4 inhibitor comp55 and vitamin D analogues are used in combination to synergistically inhibit formation of CAFs. The application first proposes that PAK4 inhibitor comp55 and anti-PD-1 antibodies are used in combination to synergistically inhibit formation of CAFs. The application first proposes that PAK4 inhibitor comp55, vitamin D analogues and anti-PD-1 antibodies are used in combination to significantly inhibit tumor growth, inhibit formation of CAFs, promote CD8 + T cell infiltration and IFN-gamma secretion.

The present application relates to the field of detection reagent, especially to a vitamin A analogue, a synthesis method and application thereof. The present application provides a vitamin A analogue, a synthesis method and application thereof. The vitamin A analogue has relatively low cost, can be synthesized in large scale, and has certain difference from vitamin A in mass spectrum, and can be used as an internal standard of vitamin A to detect vitamin A.

The present application relates to a method and application of preparing a vitamin D dry powder raw material wrapped by a nano fat emulsion in the technical field of vitamin D raw material preparation, and it comprises the following steps: weighing the preparation material, the preparation material includes the following components and their mass percentages: fat-soluble vitamin D or vitamin D analog 0.5-20%, solubilizing component 1-5%, lecithin packaging material 1.5-10%, auxiliary packaging material 0.1-1%, antioxidant 0.01-0.05% and ion complexing agent 0.01-0.02%, and the remainder is excipient; the solubilizing component, fat-soluble vitamin D or vitamin D analog, lecithin packaging material, auxiliary packaging material, antioxidant and ion complexing agent are mixed to form colostrum; colostrum is homogenized by high pressure to a particle size of less than 500nm to obtain a fat emulsion vitamin D liquid; excipients are added to the fat emulsion vitamin D liquid, stirring and dissolving after filtering through a filter membrane, drying, and then crushing and sieving to obtain a nano fat emulsion wrapped vitamin D dry powder raw material. The present application can improve the stability and bioavailability of vitamin D raw materials.

The present disclosure relates to the topical treatment of skin diseases such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratosis, pachyonychia congenita, multiple sebaceous cysts, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and keratinization disorders using (a) a JAK inhibitor or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.

The invention relates to the field of medicines, in particular to a liver cancer treatment medicine composition with a synergistic effect and application of the liver cancer treatment medicine composition in preparation of medicines for treating liver cancer, and the medicine composition is composed of a vitamin D analogue and a PD-1 inhibitor. The pharmaceutical composition disclosed by the invention can amplify cascade reaction of an IFN-gamma signal channel in a tumor and activate anti-tumor immunity, so that the effect of killing liver cancer is achieved; a subcutaneous tumor-bearing model, a liver cancer in-situ model and a liver cancer patient organ respectively prove that the vitamin D analogue paricalcitol can obviously improve the curative effect of the PD-1 inhibitor. The vitamin D analogue paricalcitol is a clinically mature drug, has low drug toxicity, small side effects after long-term use and convenient clinical application, can significantly improve the sensitivity of liver cancer to a PD-1 inhibitor, and provides a new strategy for treatment of liver cancer.

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and / or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.

The invention discloses a supported photosensitizer as well as a preparation method and application thereof in photocatalysis, and belongs to the technical field of photosensitizers. The preparation method comprises the following steps: A, a reductive amination method: taking chitosan as a raw material, catalyzing with an aromatic aldehyde monomer by adopting acid at room temperature to form a Schiff base, and then reacting with a reducing agent in situ; and B, a nucleophilic substitution method: taking chitosan as a raw material, and carrying out alkylation reaction on the chitosan, an aryl chloromethane monomer and amino on a chitosan chain under alkaline conditions. The supported photosensitizer retains the activity of a homogeneous catalyst in double-bond cis-trans isomerization of vitamin D analogues, and after the reaction is completed, the advantages of separation, recovery, reusability and even continuous flow production can be realized by adding an alcohol solvent in a proper proportion.